Dual-payload ADCs stand out in cancer therapy for their potential to target multiple pathways or overcome resistance—yet their development demands precise payload conjugation and controlled DAR, key challenges in manufacturing.
WuXi XDC’s Scaffold Library for Branched Linkers addresses these hurdles head-on. Our linkers enable sequential/simultaneous payload conjugation, leveraging selective deprotection (for controlled DAR) and orthogonal click chemistry for reliable production.
Diverse, updated linkers fit preclinical-clinical needs. Backed by experts, we deliver end-to-end support—speeding R&D, cutting costs, and advancing dual-payload ADC therapies.